

REGENERON

SCIENCE TO MEDICINE®

We are a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our priority citizenship commitment has been to support the future of scientific innovation. As part of this ongoing commitment, we are honored and humbled to be the next title sponsor of the Science Talent Search, an opportunity to recognize and energize the next generation of groundbreaking minds.

We are proud to have several STS alumni among our employee base, including Leonard Schleifer, MD, PhD, our Founder, President and Chief Executive Officer, and George Yancopoulos, MD, PhD, our Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer.

REGENERON

SCIENCE TALENT SEARCH

A program of
SOCIETY FOR SCIENCE
& THE PUBLIC



Since 1942





FOUNDED IN 1988

- Launched and led for nearly 30 years by physician-scientists who apply cutting-edge science to create new medicines for debilitating diseases
- Locations in NY, NJ and Ireland, with headquarters in Tarrytown, NY
- 4,000+ employees worldwide, including 630 with MD, PhD or PharmD degrees

FDA-APPROVED MEDICINES THAT HELP:

- Restore vision for people with serious eye diseases
- Lower high cholesterol in certain people
- Treat a rare genetic disease

12+ INVESTIGATIONAL MEDICINES IN CLINICAL TRIALS

- Only biotech of our size with 100% of pipeline candidates discovered in-house
- Broad approach to exploring new treatments for multiple serious diseases, including cancer, inflammation, asthma and pain

DRIVEN BY SCIENCE

- Deep expertise in and focus on biology, mouse genetics and human genetics
- Deeply committed to STEM education to support the development of highly engaged, well-trained and innovative young thinkers
- As title sponsor of the Regeneron Science Talent Search, we strive to encourage the best and brightest minds to pursue careers in science

TECHNOLOGY LEADER

- Proprietary VelociSuite® technologies were designed to address drug development bottlenecks, and enable targeted, efficient study of disease and the creation of new therapeutics
- Created the Regeneron Genetics Center, one of the world's largest integrated programs of its kind, to enable a deeper understanding of how human genetics impact disease

AMONG TOP BIOPHARMA INVESTORS IN R&D

- Increased our R&D spending by 88% since 2013
- Committed to building new technologies and advancing even more investigational medicines for patients in need



To learn more about us, please visit:

REGENERON.COM

 @REGENERON